NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 - Université de Lille
Article Dans Une Revue EFSA Journal Année : 2018

NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Jean-Louis Bresson
  • Fonction : Auteur
Barbara Burlingame
  • Fonction : Auteur
Tara Dean
  • Fonction : Auteur
Susan Fairweather-Tait
  • Fonction : Auteur
Marina Heinonen
  • Fonction : Auteur
Karen-Ildico Hirsch-Ernst
  • Fonction : Auteur
Inge Mangelsdorf
  • Fonction : Auteur
Harry J. Mcardle
  • Fonction : Auteur
Androniki Naska
  • Fonction : Auteur
Monika Neuhauser-Berthold
  • Fonction : Auteur
Grazyna Nowicka
  • Fonction : Auteur
Kristina Pentieva
  • Fonction : Auteur
Yolanda Sanz
  • Fonction : Auteur
Anders Sjodin
  • Fonction : Auteur
Martin Stern
  • Fonction : Auteur
Daniel Tome
  • Fonction : Auteur
Henk van Loveren
  • Fonction : Auteur
Marco Vinceti
  • Fonction : Auteur
Peter Willatts
  • Fonction : Auteur
Ambroise Martin
  • Fonction : Auteur
Sean Strain
  • Fonction : Auteur
Alfonso Siani
  • Fonction : Auteur

Résumé

Following an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to NWT-02 and a reduction of the loss of vision. The food proposed by the applicant as the subject of the health claim is NWT-02. NWT-02 is standardised by its content in lutein (≥ 1.10 mg), zeaxanthin (≥ 0.20 mg) and docosahexaenoic acid (DHA) (≥ 170 mg). The Panel considers that the food/constituent that is the subject of the health claim, NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, is sufficiently characterised. The claimed effect proposed by the applicant is ‘reduces loss of vision’. The target population proposed by the applicant is ‘healthy adults over 50 years of age’. The Panel considers that a reduction of the loss of vision is a beneficial physiological effect. The applicant provided two human intervention studies for the scientific substantiation of the claim. The Panel considers that the only study from which conclusions can be drawn for the scientific substantiation of the claim did not show an effect of NWT-02 on vision. The Panel concludes that a cause and effect relationship has not been established between the consumption of NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, and a reduction of the loss of vision.
Fichier principal
Vignette du fichier
EFSA Journal - 2018 - - NWT‐02 a fixed combination of lutein zeaxanthin and docosahexaenoic acid in egg yolk and.pdf (740.31 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04318499 , version 1 (01-12-2023)

Licence

Identifiants

Citer

Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, et al.. NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal, 2018, EFSA Journal, 16, ⟨10.2903/j.efsa.2018.5139⟩. ⟨hal-04318499⟩

Collections

RIIP UNIV-LILLE
16 Consultations
5 Téléchargements

Altmetric

Partager

More